--- title: "Innovative drugs make a strong comeback, ASCO annual meeting opens, Hang Seng Healthcare ETF ChinaAMC (159892) surges" type: "News" locale: "en" url: "https://longbridge.com/en/news/288018559.md" description: "The ASCO Annual Meeting will be held in Chicago from May 30 to June 3, 2026. Thirteen studies from 12 Chinese innovative pharmaceutical companies have been selected for the conference, setting a historical record. The performance in the field of lung cancer treatment is outstanding, with related research covering multiple key directions. Influenced by this positive news, the Hang Seng Healthcare ETF ChinaAMC (159892) surged, leading the Hong Kong stock market" datetime: "2026-05-29T06:07:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288018559.md) - [en](https://longbridge.com/en/news/288018559.md) - [zh-HK](https://longbridge.com/zh-HK/news/288018559.md) --- # Innovative drugs make a strong comeback, ASCO annual meeting opens, Hang Seng Healthcare ETF ChinaAMC (159892) surges From May 30 to June 3, 2026, the American Society of Clinical Oncology (ASCO) will hold its conference in Chicago. According to statistics from YaoMao, 13 studies from 12 Chinese innovative pharmaceutical companies have been selected for the most significant plenary sessions and latest breakthrough abstracts (LBA), setting a historical high. The results released by Chinese innovative pharmaceutical companies cover multiple therapeutic areas, with a significant advantage in the lung cancer treatment track. Among the indications covered, lung cancer is a stronghold in China's oncology research, and this year's ASCO features studies in the lung cancer field that have been selected for LBA, focusing on key areas such as first-line treatment, brain metastasis, and ctDNA-guided personalized therapy. Driven by multiple favorable factors, the healthcare sector leads the Hong Kong stock market, with the Hang Seng Biotechnology Index, which focuses on the innovative drug industry chain, rising over 4% during the session. The largest ETF tracking this index, the ChinaAMC Hang Seng Biotechnology Technology ETF (159892), also saw gains, with companies like Innovent Biologics, 3SBio, and Yinxin Biologics leading the charge ### Related Stocks - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [09606.HK](https://longbridge.com/en/quote/09606.HK.md) - [688336.CN](https://longbridge.com/en/quote/688336.CN.md) ## Related News & Research - [CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial](https://longbridge.com/en/news/288238438.md) - [Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | AAPG Stock News](https://longbridge.com/en/news/288186853.md) - [](https://longbridge.com/en/news/288700390.md) - [15:15 ETVaniam Group and Women Leaders in Oncology Honor 2026 Young Investigator Award Recipients at ASCO](https://longbridge.com/en/news/288317167.md) - [09:00 ETDiakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026](https://longbridge.com/en/news/288867269.md)